Single versus combination intravenous antibiotic therapy for people with cystic fibrosis

Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation

“…Five symptom checklists had been used during an exacerbation, but no validation data were available. 45,[47][48][49][50] The characteristics of the 5 measures included are presented in Table 2. Their psychometrics, namely validity, reliability, responsiveness to change, and interpretability, have been assessed according to the criteria provided in the COSMIN and FDA guidelines.…”

Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation

“…Five symptom checklists had been used during an exacerbation, but no validation data were available. 45,[47][48][49][50] The characteristics of the 5 measures included are presented in Table 2. Their psychometrics, namely validity, reliability, responsiveness to change, and interpretability, have been assessed according to the criteria provided in the COSMIN and FDA guidelines.…”

Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers

“…The range and multitude of synergistic interactions suggests PPMO and antibiotic combination therapy could be clinically useful. However, although CF patients are often prescribed multiple antibiotics, there is currently no evidence for improved patient outcomes when using combination in vitro susceptibility testing results (compared to standard single compound susceptibility testing results) to inform clinical therapy for acute pulmonary exacerbation of CF (33,34). There are several limitations of this study that are worthy of mention.…”

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa

“…Es gibt keine Evidenz, dass eine Monotherapie äquivalent zu einer Kombinationstherapie ist ( 135 ; Leitlinie). Eine Cochrane-Metaanalyse ( 136 137 ; Evidenzlevel 1) verglich 43 Studien (Monotherapien vs. Kombinationstherapien) und kam aufgrund unterschiedlicher methodischer Qualität, Patient*innenzahlen pro Studie und Einschluss auch von historischen Publikationen vor 1988 zu keinem eindeutigen Ergebnis bei ungenügender Evidenz. In den Nachuntersuchungen nach 2–8 Wochen fand sich ein nicht signifikanter Trend zu mehr Resistenzbildungen bei Monotherapie im Vergleich zur Kombinationstherapie.…”

Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation

“…Five symptom checklists had been used during an exacerbation, but no validation data were available. 45,[47][48][49][50] The characteristics of the 5 measures included are presented in Table 2. Their psychometrics, namely validity, reliability, responsiveness to change, and interpretability, have been assessed according to the criteria provided in the COSMIN and FDA guidelines.…”

Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers

“…The range and multitude of synergistic interactions suggests PPMO and antibiotic combination therapy could be clinically useful. However, although CF patients are often prescribed multiple antibiotics, there is currently no evidence for improved patient outcomes when using combination in vitro susceptibility testing results (compared to standard single compound susceptibility testing results) to inform clinical therapy for acute pulmonary exacerbation of CF (33,34). There are several limitations of this study that are worthy of mention.…”

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa

“…Es gibt keine Evidenz, dass eine Monotherapie äquivalent zu einer Kombinationstherapie ist ( 135 ; Leitlinie). Eine Cochrane-Metaanalyse ( 136 137 ; Evidenzlevel 1) verglich 43 Studien (Monotherapien vs. Kombinationstherapien) und kam aufgrund unterschiedlicher methodischer Qualität, Patient*innenzahlen pro Studie und Einschluss auch von historischen Publikationen vor 1988 zu keinem eindeutigen Ergebnis bei ungenügender Evidenz. In den Nachuntersuchungen nach 2–8 Wochen fand sich ein nicht signifikanter Trend zu mehr Resistenzbildungen bei Monotherapie im Vergleich zur Kombinationstherapie.…”

Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation

“…Five symptom checklists had been used during an exacerbation, but no validation data were available. 45,[47][48][49][50] The characteristics of the 5 measures included are presented in Table 2. Their psychometrics, namely validity, reliability, responsiveness to change, and interpretability, have been assessed according to the criteria provided in the COSMIN and FDA guidelines.…”

Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers

“…The range and multitude of synergistic interactions suggests PPMO and antibiotic combination therapy could be clinically useful. However, although CF patients are often prescribed multiple antibiotics, there is currently no evidence for improved patient outcomes when using combination in vitro susceptibility testing results (compared to standard single compound susceptibility testing results) to inform clinical therapy for acute pulmonary exacerbation of CF (33,34). There are several limitations of this study that are worthy of mention.…”

S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa

“…Es gibt keine Evidenz, dass eine Monotherapie äquivalent zu einer Kombinationstherapie ist ( 135 ; Leitlinie). Eine Cochrane-Metaanalyse ( 136 137 ; Evidenzlevel 1) verglich 43 Studien (Monotherapien vs. Kombinationstherapien) und kam aufgrund unterschiedlicher methodischer Qualität, Patient*innenzahlen pro Studie und Einschluss auch von historischen Publikationen vor 1988 zu keinem eindeutigen Ergebnis bei ungenügender Evidenz. In den Nachuntersuchungen nach 2–8 Wochen fand sich ein nicht signifikanter Trend zu mehr Resistenzbildungen bei Monotherapie im Vergleich zur Kombinationstherapie.…”